Icodextrin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Icodextrin: From Peritoneal Dialysis to Irritable Bowel Syndrome
One-Sentence Summary
Icodextrin is a high-molecular-weight glucose polymer used as an osmotic agent in peritoneal dialysis solutions. The TxGNN model predicts it may be effective for irritable bowel syndrome, but this is a model prediction only, with 0 clinical trials and 0 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore license data (the product is a peritoneal dialysis solution) |
| Predicted New Indication | Irritable bowel syndrome |
| TxGNN Prediction Score | 98.53% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, icodextrin is a glucose polymer that acts as a colloid osmotic agent in peritoneal dialysis, and it is minimally absorbed from the gut.
The data compiled for this report show no clear mechanistic link between this action and irritable bowel syndrome. The high score (0.985) reflects a knowledge-graph prediction, and no biological rationale for this indication is supported by the available data. The model ranked this prediction 14,036th overall, so the score alone should be interpreted with caution.
Other top-ranked predictions (for example C1 inhibitor deficiency, serpinopathy, hereditary angioedema, familial visceral myopathy, and renal tubular acidosis) also lack any supported mechanism, no clinical trials and no publications. They appear to reflect graph structure rather than biology. For hereditary angioedema, documented hypersensitivity reactions to icodextrin argue for caution rather than benefit.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN11220P | EXTRANEAL Peritoneal Dialysis Solution 75 g/l | Sterile solution | Not stated in the license data |
Safety Considerations
Please refer to the package insert for safety information.
Documented hypersensitivity reactions to icodextrin warrant caution in any new use.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on the model score. There are no clinical trials, no publications, and no plausible mechanism linking an osmotic peritoneal dialysis agent to irritable bowel syndrome, so the evidence level is L5.
To proceed, the following is needed:
- Mechanism of action data for icodextrin, and a biological rationale for irritable bowel syndrome
- Package insert warnings and contraindications from the Health Sciences Authority (HSA), as the safety screening cannot proceed without them
- The approved indication text for the Singapore license
- Preclinical or observational evidence supporting a benefit in irritable bowel syndrome
- Assessment of route compatibility, since the current product is a peritoneal dialysis solution
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.